|
|
|
|
|
|
|
M T W Thu F |
|
27 August, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
Lilly’s decision to stop publishing its Phase 1 pipeline may give it a competitive advantage over its fast-acting Chinese rivals. But it also shows a lack of transparency at a time when the public is already distrustful of big pharma. Kyle LaHucik spoke with analysts and former Lilly Research Labs presidents about the early-stage shielding. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Kyle LaHucik
|
As its world-leading GLP-1 earns more than any other medicine— and its market cap eclipses all other healthcare companies — Eli Lilly has decided... | |
|
|
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus news about Takeda China and ProFound. Moderna's $2B offering: The mRNA biotech will offer convertible senior notes
for the "flexibility to invest" in growing... | |
|
|
|
|
|
|
by Ayisha Sharma
|
Generate:Biomedicines shared Phase 1 data for its respiratory disease drug as part of the European Respiratory Society's (ERS) annual meeting after posters were prematurely released... | |
|
|
|
|
|
